TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Best Available Therapy With or Without Meropenem for Bloodstream Infections by Enterobacterales With High Level of Resistance to Carbapenems

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Primary or secondary bloodstream infections by any specie of the Enterobacterales family with minimum inhibitory concentration (MIC) for meropenem \>32mg/L;~* Agreement of the assistant team with the inclusion of the patient in the study;~* Agreement by the patient or legal guardian to sign the informed consent form.~Exclusion Criteria:~* Known pregnancy;~* Patients belonging to the population deprived of their liberty;~* Known allergy to meropenem;~* Use of ceftazidime-avibactam (or any other new antimicrobial agent that become available in Brazil during the study period) for the treatment of the current infection;~* Infection by an Enterobacterales isolates without in vitro susceptibility to at least one antimicrobial drug;~* Bloodstream co-infection by another gram negative bacilli;~* Concomitant infection at any site by a pathogen which meropenem is indicated;~* Neutropenia (\<1000 neutrophils cells/mm3)~* Death expected within 48 hours of eligibility assessment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Meropenem plus Best Available Therapy plus (Type: EXPERIMENTAL): Meropenem 2g every 8 hours combined with the best available therapy (BAT). BAT will be defined according to the susceptibility profile and decision of the assistant team before randomization and should include at least one of the antimicrobials that, usually, have in vitro activity against carbapenem-resistant Enterobacterales isolates.~1. Polymyxin B or colistimethate;~2. Amikacin or gentamicin;~3. Tigecycline;~4. Another antimicrobial with in vitro susceptibility.~Doses will be defined by the assistant team.
- Best Available Therapy (Type: NO_INTERVENTION): The best available therapy will be defined according to the susceptibility profile and decision of the assistant team before randomization and should include at least one of the antimicrobials that, usually, have in vitro activity against carbapenem-resistant Enterobacterales isolates.~1. Polymyxin B or colistimethate;~2. Amikacin or gentamicin;~3. Tigecycline;~4. Another antimicrobial with in vitro susceptibility.~Doses will be defined by the assistant team.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare Different Light Therapies (Narrowband Ultraviolet B vs PUVA) for Hand and Foot Skin Diseases.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Bilateral hand or foot skin disease (dermatitis, psoriasis, etc.) with symmetric distribution and severity.~Exclusion Criteria:~Age \<18 years Pregnancy Liver disease Kidney disease History of skin cancer Phototherapy or systemic therapy for the skin condition in the preceding 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Narrowband Ultraviolet B (TL-01UVB) Therapy (Type: ACTIVE_COMPARATOR): treatments - 3x weekly for 15 months
- Topical Psoralen plus ultraviolet A (PUVA) (Type: ACTIVE_COMPARATOR): Treatments - 3x weekly for 15 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Percussion Device (PD) for Detection of Pneumothorax

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients that have undergone an open or thoracoscopic thoracic procedure requiring a chest tube at London Health Sciences Centre (LHSC), London, Ontario.~Exclusion Criteria:~* Patients less than 18 years old Patients unable to consent Patients with known persistent pneumothorax prior to chest tube removal Patients who are pregnant Patients with severe chest wall deformity.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PD arm (Type: EXPERIMENTAL): Patients undergoing assessment of the chest with the percussion device (PD).
- US arm (Type: ACTIVE_COMPARATOR): Patients undergoing assessment of the chest with the ultrasound (US).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Watch and Wait After Neo-adjuvant Chemoradiotherapy for Primary Locally Advanced Rectal Cancer.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically verified adenocarcinoma of the rectum within 15 cm from the anal verge measured by rigid proctoscopy~* Patients who have completed neoadjuvant treatment according to national guidelines for rectal cancer, i.e., radiotherapy or chemo-radiotherapy (at least 40 Gy) or short-course radiotherapy combined with chemotherapy~* Patients aged ≥18 years of age are eligible for inclusion. However, patients aged ≤40 years are recommended to undergo surgery on the theoretical base of a possibly more aggressive tumour disease in this age group, and will be asked to participate in the study by consenting to recording of data. Those patients who insist on W\&W approach after careful consideration and well-documented informed consent are eligible for entering the W\&W protocol.~* Given informed consent~* Stage I-III rectal cancer; however, patients with limited liver metastases who undergo primary liver surgery as part of a liver first treatment approach may be included~Exclusion Criteria:~* Patients without cCR~* Patients unable to give informed consent~* Patients with short course radiotherapy (5x5 Gy) without additional chemotherapy, or patients receiving less than 40 Gy in long course CRT~* Patients with cCR but with increasing tumour growth on MRI after preoperative treatment~* Patients with metastatic disease at the time of diagnosis with the exception of those who are eligible for liver first treatment approach as part of an intention to cure approach.~* Patients previously diagnosed and treated for malignant disease in the pelvic region with radio- or chemoradiotherapy~* Other circumstances that may interfere with successful participation in the W\&W protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Temzolomide and Gleevec in Advanced Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed melanoma that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective~* Prior chemotherapy, immunotherapy, radiation therapy (Phase I portion only), cytokine, biologic, or vaccine therapy is permitted, however no prior treatment with temozolomide~* Measurable disease~* Performance status \<= 2~* Life expectancy greater than 3 months~Exclusion Criteria:~* No prior treatment with temozolomide or imatinib mesylate~* Organ allografts~* Prior radiotherapy, or prior intratumor injection therapy, to areas of measurable disease that are used as target indicator lesions, unless progression has occurred at that site or measurable disease has developed outside the treatment area~* Pregnancy or lactation~* History of second cancer~* Known hypersensitivity to temozolomide or imatinib~* Use of any experimental therapy within 3 weeks prior to baseline evaluations done prior to enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: (Type: EXPERIMENTAL): Temozolomide plus imatinib

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Omega 6:Omega 3 Ratio and Progression of Age-related Macular Degeneration (AMD).

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 50+ years of age~* NVAMD (Wet) in one eye, early or intermediate dry-AMD in the fellow eye~* taking AREDS vitamins (or equivalent)~Exclusion Criteria:~* Central geographic atrophy~* Diabetic retinopathy~* Ocular surgery in the eye with dry-AMD (not including cataract IOL surgery)~* Underlying ocular pathology in the eye with dry-AMD (especially glaucoma, dense cataracts, and retinitis pigmentosa)

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosed plaque psoriasis for at least six months with multiple treatable areas (i.e. the lesion should not only on the face, scalp, genitals or skinfolds) which covers less than 10% of the total Body Surface Area (BSA), and affected area on the limb and/or trunk ≥ 1% BSA. The long diameter and thickness of target plaque psoriasis was ≥ 2cm and ≥2, respectively.~* In good health condition, with no history of diseases of major organs and no abnormality found on physical examination and vital signs.~* Men and women of childbearing potential must agree to use a contraceptive regimen agreed by the doctor during the trial. Female subjects that are on hormonal contraceptives must continue using the same hormonal contraceptive as that was used in the past 3 months, with the same route of administration and the same dose during the whole study.~* Have signed a written informed consent before entering the study.~Exclusion Criteria:~* Psoriasis guttata, psoriasis punctata, erythrodermic psoriasis, pustular psoriasis, psoriasis arthritis.~* Evidence of skin conditions other than psoriasis that would interfere with evaluations of the effect of study medication on psoriasis.~* Drug-induced psoriasis.~* Present with or had historical interstitial lung disease.~* In the opinion of the investigator, the subjects were not considered appropriate candidates.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): 65 patients with mild to moderate psoriasis will be randomized to receive 1% Icotinib hydrochloride cream, applied twice daily for 12 consecutive weeks. The drug will be applied topically to the psoriasis site.
- Cohort 2 (Type: EXPERIMENTAL): 65 patients with mild to moderate psoriasis will be randomized to receive 2% Icotinib hydrochloride cream, applied twice daily for 12 consecutive weeks. The drug will be applied topically to the psoriasis site.
- Cohort 3 (Type: EXPERIMENTAL): 65 patients with mild to moderate psoriasis will be randomized to receive 4% Icotinib hydrochloride cream, applied twice daily for 12 consecutive weeks. The drug will be applied topically to the psoriasis site.
- Cohort 4 (Type: PLACEBO_COMPARATOR): 65 patients with mild to moderate psoriasis will be randomized to receive placebo cream (blank cream containing no icotinib hydrochloride), applied twice daily for 12 consecutive weeks. The drug will be applied topically to the psoriasis site.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Cranial Electro Therapy Stimulation in Reducing Perioperative Anxiety

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients of both genders between 50 and 90 years old scheduled for an outpatient first eye cataract phacoemulsification with topical anesthesia.~* ASA classification I II and III~Exclusion Criteria:~* ASA classification IV (patients with a chronic or severe disease).~* Hypersensitivity to midazolam or benzodiazepines~* acute narrow-angle glaucoma~* untreated open-angle glaucoma~* Patients with any sort of psychiatric or neurological disorder~* Patients on anti-anxiety medication~* Patients who have demand-type pacemakers installed before 1999\* \*Note: These are the exclusions listed for liability purposes by Alpha-Stim. There are no FDA exclusions.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Alpha-Stim intervention (Type: ACTIVE_COMPARATOR): One hour Alpha-Stim intervention with sham midazolam
- Sham Alpha-Stim with midazolam (Type: SHAM_COMPARATOR): Sham Alpha-Stim intervention with real midazolam administration
- Placebo (Type: PLACEBO_COMPARATOR): No Alpha-Stim and only topical anesthetics

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Changes in Brown Adipose Tissue Activity In Men Receiving Androgen Deprivation Therapy for Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adenocarcinoma of the prostate~* Scheduled to initiate GnRH agonist or antagonist treatment with an intended treatment duration of 12 months or greater~* ECOG Performance status of 0 or 1~* Ability to understand and the willingness to sign a written informed consent~* 65 years of age or younger~Exclusion Criteria:~* Diagnosis of diabetes~* Ongoing corticosteroid use~* GnRH agonist or antagonist treatment within the last 2 years~* Ongoing beta-blocker use~* Body mass index of greater than 30

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* 1. Patient successfully completed the Phase 1b/2a study with WVE-120101, WVE-HDSNP1-001.~Key Exclusion Criteria:~* 1. Received an investigational drug other than WVE-120101, including an investigational oligonucleotide, within the past 1 year or 5 half-lives of the drug, whichever is longer.~* 2. Inability to undergo brain MRI (with or without sedation).~* 3. Clinically significant medical finding on the physical examination other than HD that, in the judgment of the Investigator, will make the patient unsuitable for participation in and/or completion of the study procedures.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- WVE-120101 (Dose A) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Research and Analysis of the Mechanisms Involved in the Emergence of Breast Cancer Stem Cells (RepriM)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Women over 18~* With a mammary adenocarcinoma histologically proven~* Who cannot benefit from a first-conserving surgery or with aggressiveness criteria on the initial biopsy (triple negative tumor, grade III histoprognostic, high Ki67, HER2 overexpressed) after presentation in multidisciplinary meeting.~* Absence of prior chemotherapy.~* Requiring a neoadjuvant chemotherapy with anthracyclines and taxanes selected in multidisciplinary meeting.~* Informed consent signed by the patient before the implementation of any specific procedure to the study.~Exclusion Criteria:~* Metastatic disease. The extension work-up is carried out according to the reference system of the participating center.~* Other histological type.~* Patient refusing the conservation of samples.~* Patient included in a clinical trial protocol with an experimental molecule (during this study).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Biological collection (Type: EXPERIMENTAL): Before, during and after their treatment by chemotherapy, patients will undergo laboratory examinations.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: An Extension Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed informed consent (as applicable for the age of the subject).~2. Participation in and completion of study OC5-DB-02.~3. Subjects who had received vitamin B6 during OC5-DB-02 study should maintain a stable dose. Subjects not receiving vitamin B6 during OC5-DB-02 must be willing to refrain from initiating pyridoxine during study participation.~Exclusion Criteria:~1. Inability to swallow size 4 capsules.~2. Use of antibiotics to which O. formigenes is sensitive.~3. Current treatment with a separate ascorbic acid preparation.~4. Pregnant or lactating women (or women who are planning to become pregnant).~5. Women of childbearing potential who are not using adequate contraceptive precautions.~6. Presence of a medical condition that the Investigator considers likely to make the subject susceptible to adverse effect of study treatment or unable to follow study procedures or any condition that is likely to interfere with the study drug mechanism of action (such as abnormal GI function).~7. Participation in any interventional study of another investigational product, biologic, device, or other agent or not willing to forego other forms of investigational treatment during this study.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oxabact OC5 capsules (Type: EXPERIMENTAL): Oxabact OC5 - Oxalobacter formigenes Strain HC-1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Stroke-free Survival Comparison Between Early Surgery and Conventional Therapy in Left Infective Endocarditis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Left-sided Infective Endocarditis (IE) according to modified Duke criteria, fulfilling at least one of the following features:~   * IE on native or prosthetic valve with severe mitral or aortic valve regurgitation, without heart failure;~  * IE on native or prosthetic valve, during the first week of antibiotic therapy, have very large (15-30 mm) or large (\>10mm), mobile isolated vegetations due to Staphylococcus aureus, Streptococcus bovis, HACEK or Abiotrophia, without any other indication for surgery;~  * IE on native or prosthetic valve with severe valve regurgitation without heart failure and with large vegetations (\> 10 mm) and Euroscore I 5-19;~  * IE on native or prosthetic valve with moderate o moderate-severe valve regurgitation with large vegetations (\> 10 mm)~  * IE on prosthetic valve due to Staphylococcus aureus or gram negative non HACEK microorganisms.~2. Compliance to study treatments~3. Euroscore I \<20~4. Informed consent signature~Exclusion Criteria:~1. Patients with right-side IE and IE on a cardiac device~2. Patients with IE and:~   * heart failure , refractory pulmonary oedema, cardiogenic shock or untreatable heart failure~  * fistula involving cardiac chambers or pericardium~  * persistent heart failure or unstable echocardiographic signs or poor haemodynamic tolerance~  * uncontrolled local infection (abscess, pseudoaneurism, fistula, increase in size vegetations)~  * fever and positive blood cultures lasting \>7 days~  * fungal IE or other multi-resistant microorganisms~  * large vegetations (\> 10 mm) after embolic event~  * large vegetations (\> 10 mm) and other predictors of complicated course (heart failure, abscess)~  * vegetations \>30 mm

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Early surgery (Type: EXPERIMENTAL): Surgery within 72 hours from endocarditis diagnosis
- Conventional therapy (Type: ACTIVE_COMPARATOR): Medical treatment and a possible delayed surgical intervention according to the current guidelines

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues